Leerink Partners Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its target price cut by Leerink Partners from $8.50 to $5.50 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “market perform” rating on the health services provider’s stock. Leerink Partners’ price objective would indicate a potential upside of 1.76% from the stock’s previous close.

Several other equities research analysts have also commented on the stock. TD Cowen decreased their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday. Evercore reduced their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a report on Thursday, October 30th. Citigroup dropped their price target on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, January 9th. Stifel Nicolaus reduced their price objective on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday. Finally, Zacks Research cut Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.93.

Teladoc Health Stock Up 16.2%

NYSE TDOC traded up $0.76 on Thursday, reaching $5.41. The company had a trading volume of 18,495,312 shares, compared to its average volume of 6,881,845. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. The company’s fifty day moving average is $6.06 and its 200 day moving average is $7.22. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $10.02. The stock has a market capitalization of $959.23 million, a P/E ratio of -4.21 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The firm had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The business’s revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Sell-side analysts anticipate that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Carlos Nueno sold 3,897 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $29,188.53. Following the sale, the insider owned 27,175 shares in the company, valued at $203,540.75. This represents a 12.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Fernando M. Rodrigues sold 4,209 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its position in shares of Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after buying an additional 2,810 shares in the last quarter. IFP Advisors Inc increased its stake in Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after acquiring an additional 3,210 shares during the last quarter. Aster Capital Management DIFC Ltd raised its holdings in shares of Teladoc Health by 101.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after acquiring an additional 2,425 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Teladoc Health during the 4th quarter valued at about $45,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Teladoc Health during the 3rd quarter valued at about $58,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results topped expectations: Teladoc posted a narrower-than-expected GAAP loss (EPS -$0.14 vs. -$0.19 consensus) and revenue of $642.3M slightly above estimates, driven by international and Integrated Care strength which helped offset BetterHelp weakness. Teladoc Tops Q4 Earnings
• Positive Sentiment: Bank of America upgraded TDOC from Neutral to Buy and set a $7 price target, signaling conviction from a large shop and providing buy-side momentum. BofA Upgrade
• Positive Sentiment: Piper Sandler reaffirmed an Overweight rating with a $9 price target (albeit reduced from $12), underscoring that some sell-side analysts still see meaningful upside based on recovery potential. Piper Sandler Note
• Neutral Sentiment: Company provided forward revenue range for 2026 ($2.47B–$2.59B) and emphasized investments in AI, insurance partnerships, and international expansion — strategic positives, but longer‑term and already partly baked into expectations. 2026 Revenue Projection
• Neutral Sentiment: Investors can review the full earnings call transcript and slide deck for detail on segment trends and cost actions; useful for modeling but not immediate catalysts by themselves. Earnings Call Transcript Slide Deck
• Negative Sentiment: Guidance was weaker than Street expectations: Q1 EPS guide (-$0.45 to -$0.35 vs. est -$0.28) and Q1 revenue guide ($598M–$620M vs. est ~$633M) came in below consensus, and FY EPS range (-$1.10 to -$0.70) is wider/poorer than modeled — a primary reason for intra‑day pressure before buyers stepped in. Earnings & Guidance
• Negative Sentiment: Several firms trimmed price targets and lowered ratings (Cowen to $6 Hold, BMO to $5 Market Perform, Wells Fargo to $6 Equal Weight, Stifel to $6 Hold), signaling more cautious near‑term views from parts of the sell side and creating downward pressure despite the beat. Analyst PT Cuts BMO Note

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.